Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
NBIX Neurocrine Biosciences, Inc. monthly Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E758.12 EPS (ttm)0.13 Insider Own1.00% Shs Outstand91.39M Perf Week4.58%
Market Cap9.21B Forward P/E28.64 EPS next Y3.52 Insider Trans-31.88% Shs Float90.38M Perf Month2.52%
Income18.10M PEG- EPS next Q0.63 Inst Own- Short Float4.23% Perf Quarter18.62%
Sales605.20M P/S15.23 EPS this Y113.70% Inst Trans1.58% Short Ratio5.71 Perf Half Y18.47%
Book/sh5.29 P/B19.06 EPS next Y304.13% ROA1.80% Target Price111.33 Perf Year-14.12%
Cash/sh6.78 P/C14.86 EPS next 5Y- ROE4.00% 52W Range64.72 - 125.59 Perf YTD41.20%
Dividend- P/FCF208.48 EPS past 5Y18.30% ROI4.20% 52W High-19.71% Beta1.21
Dividend %- Quick Ratio7.30 Sales past 5Y174.10% Gross Margin99.00% 52W Low55.79% ATR2.92
Employees585 Current Ratio7.40 Sales Q/Q89.50% Oper. Margin1.60% RSI (14)61.18 Volatility2.68% 3.07%
OptionableYes Debt/Eq0.00 EPS Q/Q925.30% Profit Margin3.00% Rel Volume1.20 Prev Close101.50
ShortableYes LT Debt/Eq0.82 EarningsOct 28 AMC Payout0.00% Avg Volume668.70K Price100.83
Recom1.80 SMA202.77% SMA506.88% SMA20018.42% Volume799,820 Change-0.66%
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-07-18Initiated Stifel Buy $137
Feb-22-18Reiterated Needham Buy $95 → $110
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Oct-18-16Initiated Needham Buy $62
Sep-18-19 09:31AM  Buy These 7 Small Drugmakers to Boost Your Portfolio's Health Zacks
Sep-17-19 04:11PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® PR Newswire
Sep-11-19 04:01PM  Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors PR Newswire
Sep-05-19 09:40AM  HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Sep-04-19 09:15AM  Lannett (LCI) Hits 52-Week High, Can the Run Continue? Zacks
Aug-28-19 04:01PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Aug-26-19 09:06AM  Is Neurocrine Biosciences (NBIX) a Great Growth Stock? Zacks
Aug-20-19 03:54PM  Edited Transcript of NBIX earnings conference call or presentation 29-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
08:33AM  Should You Be Worried About Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) 3.7% Return On Equity? Simply Wall St.
01:03AM  Another 1% Rally Provides a Strong Start to the Week Zacks
Aug-14-19 09:53AM  Why Neurocrine (NBIX) Could Be Positioned for a Surge Zacks
Aug-13-19 09:36AM  Moving Average Crossover Alert: Neurocrine Biosciences Zacks
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-09-19 09:25AM  Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks
08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 09:16PM  Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $7.6 million of Shares GuruFocus.com
Aug-07-19 11:20AM  Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 08:30AM  AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women PR Newswire
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
10:20AM  Why Neurocrine (NBIX) Might be Well Poised for a Surge Zacks
Jul-30-19 12:25PM  Why Neurocrine Biosciences Stock Is Jumping Today Motley Fool +10.33%
07:50AM  Dow Jones Futures: Beyond Meat Leads 5 Key Movers; Apple Earnings Loom Investor's Business Daily
06:00AM  Neurocrine Biosciences Posts Sizzling Sales Growth in Q2 Motley Fool
05:23AM  Neurocrine Biosciences Inc (NBIX) Q2 2019 Earnings Call Transcript Motley Fool
Jul-29-19 05:25PM  Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates Zacks
04:01PM  Neurocrine Biosciences Reports Second Quarter 2019 Financial Results PR Newswire
Jul-26-19 08:31AM  Should You Buy Neurocrine (NBIX) Ahead of Earnings? Zacks
Jul-22-19 07:28PM  8 Health-Care Stocks for Your Portfolio Kiplinger
10:31AM  Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-15-19 10:17AM  Does Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Reflect Performance? Simply Wall St.
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
06:17AM  The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug Benzinga
Jul-10-19 04:10PM  Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease PR Newswire
Jul-08-19 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results PR Newswire
Jun-11-19 04:01PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders PR Newswire
01:49PM  Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX) Insider Monkey
Jun-04-19 04:01PM  Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire
03:12AM  Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
May-31-19 11:51AM  Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount? Simply Wall St.
May-30-19 04:01PM  Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference PR Newswire +5.99%
May-29-19 09:15AM  Not Ready to Rally Zacks
May-21-19 08:00AM  AbbVie Launches ORILISSA (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
May-20-19 08:00AM  Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life PR Newswire
May-16-19 04:01PM  Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting PR Newswire
May-08-19 09:15AM  Trade Anxieties Return with a Vengeance Zacks
May-07-19 04:01PM  Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire
May-06-19 08:00AM  Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients PR Newswire
May-05-19 09:05AM  Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting PR Newswire
09:00AM  Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations PR Newswire
Apr-30-19 04:01PM  Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting PR Newswire -5.90%
08:06AM  The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering Benzinga
Apr-29-19 10:38PM  Neurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call Transcript Motley Fool
04:15PM  Neurocrine: 1Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports First Quarter 2019 Financial Results PR Newswire
Apr-26-19 06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-20-19 08:24PM  Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ? Insider Monkey
Apr-16-19 11:31AM  Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company? Simply Wall St.
Apr-08-19 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results PR Newswire
Apr-01-19 07:45AM  Recent Analysis Shows Coca-Cola, Neurocrine Biosciences, Worthington Industries, Lennox International, Barrett Business Services, and Balchem Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-28-19 04:15PM  Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinsons Disease in the Annals of Neurology GlobeNewswire
Mar-23-19 10:02AM  2 Biotech Takeout Targets Perfect for Biogen Motley Fool
Mar-20-19 10:43AM  Sage Stock Pops on FDA Approval for Postpartum Depression Drug InvestorPlace
Mar-15-19 09:30AM  CTLT or NBIX: Which Is the Better Value Stock Right Now? Zacks
Mar-12-19 08:00AM  Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia PR Newswire
Mar-07-19 09:15AM  Stocks Slide for Third Straight Day Zacks
Mar-05-19 04:01PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Mar-01-19 12:33PM  Why These 2 Biotech Stocks Might Be Next On The Takeover List Investor's Business Daily
Feb-28-19 11:56AM  Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Is An Attractive Investment To Consider Simply Wall St.
Feb-22-19 11:31AM  Voyager Therapeutics stock jumps on 2nd Parkinson's deal American City Business Journals
Feb-21-19 06:01PM  Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-12-19 09:30AM  CTLT vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Feb-08-19 06:48AM  Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-06-19 08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 08:04PM  Neurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:35PM  Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates Zacks
05:37PM  Neurocrine: 4Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results PR Newswire
02:30PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
07:47AM  The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results Benzinga
Jan-31-19 02:45PM  Here are Boston-area biotechs pursuing Parkinson's treatments American City Business Journals
Jan-29-19 01:42PM  Here's Why Voyager Therapeutics Stock Soared as Much as 62.9% Today Motley Fool
10:31AM  Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
07:00AM  Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinsons Disease and Friedreichs Ataxia GlobeNewswire
Jan-28-19 09:33AM  Will Neurocrine Biosciences Continue to Surge Higher? Zacks
Jan-25-19 07:45AM  Analysis: Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdvisor, Ryder System, Nordstrom, and Express Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-16-19 04:01PM  New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders PR Newswire
06:57AM  4 Defensive Stocks to Buy Amid Shutdown and Brexit Zacks
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch
04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results PR Newswire
Jan-14-19 08:00AM  Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences ACCESSWIRE
Jan-11-19 04:25PM  Biotech Stocks Are Enjoying Their Best-Ever Start to the Year Bloomberg
01:32PM  Is Neurocrine Biosciences, Inc.s (NASDAQ:NBIX) CEO Overpaid Relative To Its Peers? Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-07-19 12:42PM  Neurocrine Gives Ingrezza Sales View, Updates on Pipeline Zacks +9.57%
07:15AM  Neurocrine Biosciences Is a Pharma Stock to Watch InvestorPlace
06:50AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology ACCESSWIRE
Jan-06-19 06:30PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones PR Newswire
10:56AM  Neurocrine Biosciences Looks Oversold GuruFocus.com
Jan-02-19 04:01PM  Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lippoldt DarinChief Legal OfficerSep 03Option Exercise32.996,736222,22126,839Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerSep 03Sale100.006,736673,60020,103Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerAug 27Option Exercise32.991,60052,78421,561Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 27Sale100.001,600160,00019,961Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Option Exercise32.991,66454,89521,625Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Sale100.091,664166,55519,961Aug 27 07:52 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 09Option Exercise32.993,03199,993420,628Aug 13 04:44 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Option Exercise8.6626,330228,018443,927Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Sale95.6426,3302,518,154417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Option Exercise8.662,75923,893420,356Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Sale95.122,759262,440417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Option Exercise8.6650,911440,889468,508Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Sale95.1550,9114,844,380417,597Aug 08 07:39 PM
Lippoldt DarinChief Legal OfficerJul 30Option Exercise18.1515,831287,33335,792Jul 31 07:14 PM
Bozigian Haig P.Chief Development OfficerJul 30Option Exercise38.9144,3561,725,704167,576Jul 31 07:11 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Option Exercise32.9950,0001,649,500168,408Jul 31 07:12 PM
Bozigian Haig P.Chief Development OfficerJul 30Sale92.7744,3564,114,858141,976Jul 31 07:11 PM
LYONS GARY ADirectorJul 30Sale92.0710,000920,686235,697Jul 31 07:15 PM
Lippoldt DarinChief Legal OfficerJul 30Sale92.1315,8311,458,56919,961Jul 31 07:14 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Sale92.9260,0005,575,438108,408Jul 31 07:12 PM
Bozigian Haig P.Chief Development OfficerJul 15Option Exercise32.9930,6801,012,133172,656Jul 17 07:08 PM
BENEVICH ERICChief Commercial OfficerJul 15Sale87.445,835510,20114,910Jul 17 07:06 PM
Bozigian Haig P.Chief Development OfficerJul 15Sale87.5030,6802,684,506141,976Jul 17 07:08 PM
Bozigian Haig P.Chief Development OfficerJul 11Option Exercise32.991003,299142,076Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 11Sale87.591008,759141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Option Exercise32.997,120234,889149,096Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Sale87.637,120623,958141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJun 18Option Exercise32.992,10069,279144,076Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 18Sale87.822,100184,417141,976Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 13Option Exercise20.7017,268357,469157,812Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 13Sale82.6217,2681,426,628141,976Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 03Option Exercise19.593,43567,292145,411Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerJun 03Sale85.513,435293,719141,976Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerMay 31Option Exercise19.5919,297378,028161,273Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 31Sale85.0219,2971,640,581141,976Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 24Option Exercise19.5917,486342,551159,462May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 24Sale80.0317,4861,399,434141,976May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 22Option Exercise19.591,30025,467143,276May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 22Sale80.031,300104,037141,976May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 16Option Exercise17.5866,6671,171,789176,352May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 16Sale80.1366,6675,341,893141,976May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 13Option Exercise8.6634,547299,177176,523May 15 07:23 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 13Sale75.441,657125,007118,408May 15 07:24 PM
Bozigian Haig P.Chief Development OfficerMay 13Sale75.5134,5472,608,813141,976May 15 07:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale83.5892076,89419,238Feb 08 05:11 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale84.0353144,622120,065Feb 08 05:09 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale83.5279166,06319,646Feb 08 05:10 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale84.234,096344,986417,597Feb 08 05:09 PM
Gano KyleChief Business Development OffFeb 06Sale83.5676263,67385,833Feb 08 05:07 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale83.5792076,88320,745Feb 08 05:06 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale83.5492076,859141,639Feb 08 05:06 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale88.011,357119,42717,595Feb 06 05:59 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale88.141,350118,986138,244Feb 06 05:59 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale88.194,489395,895410,185Feb 06 06:03 PM
Gano KyleChief Business Development OffFeb 05Sale88.122,434214,48280,989Feb 06 06:03 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale88.141,272112,11916,574Feb 06 06:06 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale88.091,225107,91117,482Feb 06 06:05 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale88.171,07094,338118,322Feb 06 06:04 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 04Sale88.121,375121,167117,066Feb 06 06:04 PM
Gano KyleChief Business Development OffFeb 04Sale88.141,375121,18680,117Feb 06 06:03 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 04Sale88.103,125275,321408,082Feb 06 06:03 PM
Bozigian Haig P.Chief Development OfficerFeb 04Sale88.101,375121,139137,372Feb 06 05:59 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale84.091,857156,1593,143Jan 10 04:47 PM
ABERNETHY MATTChief Financial OfficerDec 03Sale90.001,178106,0201,947Dec 06 05:54 PM
POPS RICHARD FDirectorNov 26Sale91.374,124376,79029,512Nov 27 06:58 PM
POPS RICHARD FDirectorNov 12Sale103.304,123425,89333,636Nov 13 06:18 PM
Bozigian Haig P.Chief Development OfficerNov 08Option Exercise8.6636,295314,147155,498Nov 13 04:15 PM
Bozigian Haig P.Chief Development OfficerNov 08Sale110.0036,2953,992,450135,997Nov 13 04:15 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 07Option Exercise15.453,30050,98518,618Nov 08 05:03 PM
Bozigian Haig P.Chief Development OfficerNov 07Option Exercise12.6229,399371,105151,043Nov 08 05:04 PM
Bozigian Haig P.Chief Development OfficerNov 07Sale110.1429,3993,238,132135,997Nov 08 05:04 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 07Sale110.003,300363,00015,318Nov 08 05:03 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 06Option Exercise15.455,70088,06521,018Nov 08 05:03 PM
Bozigian Haig P.Chief Development OfficerNov 06Option Exercise35.999,420339,026145,417Nov 08 05:04 PM
Bozigian Haig P.Chief Development OfficerNov 06Sale110.109,4201,037,167135,997Nov 08 05:04 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 06Sale110.025,700627,09615,318Nov 08 05:03 PM
LYONS GARY ADirectorNov 02Sale114.4115,0001,716,213245,697Nov 05 04:11 PM
POPS RICHARD FDirectorOct 29Sale107.135,500589,23737,759Oct 30 05:58 PM
open in yahoo | open in reuters | open in google